A leadership shift at Unither Pharmaceuticals is setting the stage for the next chapter of the European CDMO’s expansion. Henrik Krüpper took over as CEO on May 4, succeeding Eric Goupil, who moves to the role of Chairman after a quarter-century at the company’s helm.
Henrik Krüpper, a veteran of the specialty chemicals and pharmaceutical sectors, arrives at Unither with a mandate to build on its dominance in Blow-Fill-Seal (BFS) technology, a niche where the company produces 5 billion unit doses annually. His background, which includes executive roles at Siegfried and HCS Group, suggests a focus on operational excellence and strategic diversification, areas that will be critical as Unither navigates an increasingly competitive contract manufacturing landscape.
Eric Goupil’s legacy is one of steady growth: under his leadership, Unither expanded its global footprint, now operating eight production sites across four continents and generating €512 million in revenue in 2025. The transition, described as part of a long-planned succession, reflects the company’s ambition to maintain its momentum while adapting to evolving market demands.
Krüpper’s immediate priority? “Supporting the Group’s growth for the benefit of our clients and, ultimately, patients,” he said. With a solid industrial foundation and a culture of innovation already in place, his challenge will be to ensure Unither remains a step ahead in a sector where agility and technological edge are key.
Founded in 1993, Unither specializes in liquid formulations, including ophthalmic and asthma treatments, and employs 2,300 people worldwide.